Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3693)	5/8/2001 9:26:59 AM
From: Harold Engstrom	Read Replies (3) \| Respond to of 52153

Avonex was leading market share in Europe where Rebif is approved and that is now likely to change fast. Also, it might be possible that the FDA could act sooner than 2003 if the case can be made that Rebif is significantly better for MS sufferers. I had thought that Rebif and Avonex were the same molecule - remember when Ares Serono asked the FDA if it could just submit Biogen's data for Rebif?: "patients treated with Rebif® have a 90% greater chance of remaining relapse-free during the period of observation compared to patients treated with Avonex®." So, why the big discrepancy shown by this study?